Pattern of bone metastasis and treatment of Chinese patients with advanced non-small-cell lung cancer

doi:10.3969/j.issn.1006-7795.2015.04.004

Abstract

Abstract:

Objective To investigate the characteristics of bone metastasis, prognosis and treatment strategies of non-small cell lung cancer(NSCLC) patients in China. Methods Totally 103 metastatic NSCLC patients with bone as the first metastatic organ seen between July 1, 2010 and Dec. 31, 2013 were retrospectively reviewed. Clinical pathologic characteristics and treatment outcomes were evaluated in the 103 cases. Results Median age of the patients was 59(32~82) years. Among them, 28 patient had bone metastasis as the only relapse site and the remaining were accompanied by involvement of other locations. Most bone metastases(95.1%) were osteolytic. Overall survival of NSCLC bone metastases without visceral metastases was significantly longer than bone metastases with visceral metastases(18 months vs 14 months, P=0.048). Most NSCLC bone metastases(77.7%) were treated with chemotherapy, the response rate was 32.5%, and the clinical benefit rate was 58.8%. In terms of time to progression, there was significant difference between patients who received first-line chemotherapy and those who received the first-line targeted therapy(P=0.000). Conclusion Patients just with bone metastases had better prognosis than bone metastases patients with visceral metastases. Patients with bone metastases should receive individualized anti-cancer treatment.

Key words: non-small cell lung cancer, neoplasm metastasis, the first-line therapy, prognosis

CLC Number:

R734.2

Yao Shuyang, Wang Xin, Li Xiaoxue, Zhang Yi, Zhi Xiuyi. Pattern of bone metastasis and treatment of Chinese patients with advanced non-small-cell lung cancer[J]. Journal of Capital Medical University, 2015, 36(4): 533-536.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2015.04.004

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2015/V36/I4/533

References

[1] Kim S T, Uhm J E, Lee J, et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy[J]. Lung Cancer, 2012,75(1):82-88.
[2] Roato I, Gorassini E, Buffoni L, et al. Spontaneous osteoclastogenesis is a predictive factor for bone metastases from non-small cell lung cancer[J]. Lung Cancer, 2008,61(1):109-116.
[3] De Marinis F, Eberhardt W, Harper P G, et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel[J]. J Thorac Oncol, 2009,4(10):1280-1288.
[4] Coleman R E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies[J]. Cancer Treat Rev, 2001,27(3):165-176.
[5] Rosen L S, Gordon D, Tchekmedyian N S, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial[J]. Cancer, 2004,100(12):2613-2621.
[6] Iordanidou L, Trivizaki E, Saranti S, et al. Is there a role of whole body bone scan in early stages of non small cell lung cancer patients[J]. J BUON, 2006,11(4):491-497.
[7] Cetin K, Christiansen C F, Jacobsen J B, et al. Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study[J]. Lung Cancer, 2014,86(2):247-254.
[8] Machado M, Cruz L S, Tannus G, et al. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials[J]. Clin Ther, 2009,31(5):962-979.
[9] 唐顺,郭卫,杨荣利.127例肺癌骨转移患者随访的预后因素分析[J].中国肿瘤临床,2008,35(23):1335-1338.
[10] Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405): an open label, randomised phase 3 trial[J]. Lancet Oncol, 2010,11(2):121-128.
[11] Zhou C, Wu Y L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011,12(8):735-742.
[12] Mok T S, Wu Y L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009,361(10):947-957.
[13] 何玉明,李良平,张海琳,等.以骨转移症状首发的肺癌临床特征及误诊分析[J].临床误诊误治,2012,25(1):23-26.
[14] 谷耀伟,杨良锁,陈亚丽.单纯化疗与联合唑来膦酸治疗肺癌骨转移疼痛的疗效分析[J].中国煤炭工业医学杂志,2012,15(2):197-198.

[1]	Wang Rongrong, Tian Junping. Correlation between serum calcium and cardiovascular outcome in patients with acute coronary syndrome [J]. Journal of Capital Medical University, 2023, 44(1): 154-160.
[2]	Jia Jing, Chen Wenming, Li Yanchen. Clinical characteristics and prognostic analysis of multiple myeloma involving central nervous system [J]. Journal of Capital Medical University, 2023, 44(1): 161-166.
[3]	Yu Tianyu, Jiang Shimin, Gao Hongmei, Zou Guming, Li Wenge. Clinical and pathological risk factors for renal prognosis in patients with biopsy-proven diabetic nephropathy classified as chronic kidney disease stage 4 [J]. Journal of Capital Medical University, 2022, 43(5): 707-712.
[4]	Gu Qiang, Yu Xiaojun, Zhang Jin. Analysis of clinical characteristics and prognosis of the very old and young old patients with mild ischemic stroke [J]. Journal of Capital Medical University, 2022, 43(3): 474-479.
[5]	Zhou Qiaoyun, Huang Xiaowu, Xia Enlan, Zhao Yuting, Huang Rui. Reproductive outcomes of women treated for intrauterine adhesions following uterine artery embolization [J]. Journal of Capital Medical University, 2022, 43(3): 490-494.
[6]	Miao Zupei, Zhang Yinghua, Xiao Keling, Si Jin, Zhang Haoyu, Li Jing. Influence of obesity on the prognosis of patients with STEMI [J]. Journal of Capital Medical University, 2022, 43(2): 192-198.
[7]	Sun Jing, Shi Youwu, Jia Jun, Yang Ying, Sun Zhiwei, Du Feng, Yu Jing, Xiao Yanjie, Zhang Xiaodong. Prognostic value of peripheral blood inflammation-based markers in metastatic pancreatic cancer [J]. Journal of Capital Medical University, 2022, 43(2): 299-304.
[8]	Liu Yang, Wu Yumei, He Yue, Fan Bei, Wang Yan, Zhao Hui, Wang Ming. Rationality verification and evaluate of the 2018 International Federation of Gynecology and Obstetrics staging system for stage ⅠB cervical cancer [J]. Journal of Capital Medical University, 2021, 42(6): 1026-1032.
[9]	Wang Li, Zhang Guojun. Study on the application value of serum neuron-specific enolase in diagnosis and therapeutic effect on patients with traumatic brain injury [J]. Journal of Capital Medical University, 2021, 42(5): 715-720.
[10]	Tan Xiaogang, Zhang Yi. Progress in neoadjuvant immunotherapy for resectable non-small cell lung cancer [J]. Journal of Capital Medical University, 2021, 42(5): 862-867.
[11]	Lai Xuan, Zhang Aihua. Effect of metabolic syndrome on survival outcome of chronic kidney disease [J]. Journal of Capital Medical University, 2021, 42(4): 609-614.
[12]	Wang Weiwei, Wang Shanshan, Zhang Man. Clinical significance of kininogen 1 expression in non-small cell lung cancer biofluids and tissues [J]. Journal of Capital Medical University, 2021, 42(1): 77-82.
[13]	Wang Xin, Zhang Junxuan, Gao Jian, Shi Hanping. Immunonutrition improves the prognosis of patients with cancer [J]. Journal of Capital Medical University, 2020, 41(6): 1019-1024.
[14]	Liu Jun, Cao Qingfei, Ye Xiongjun, Chen Weinan, Zhao Haiyue, Tong Ming, Wang Yinyin, Huang Xiaobo, Chang Zhijie. Relationship between CREPT expression and prognosis in renal cell carcinoma [J]. Journal of Capital Medical University, 2020, 41(4): 552-557.
[15]	Wu Xikang, Wang Yue, He Huiying. Expression and significance of Slit guidance ligand 3 in upper tract urothelial carcinoma [J]. Journal of Capital Medical University, 2020, 41(3): 354-359.